Loading
A phase 3 trial of Prednisone and Apalutamide and Abiraterone acetate in Prostate cancer, run by Dana-Farber Cancer Institute, recorded as terminated on the registry.
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT is a phase 3 interventional study registered as NCT03777982 by Dana-Farber Cancer Institute, with 12 participants recorded, started 2020-04-20 and due to reach its primary completion in 2024-02-13. Interventions recorded: Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist. Conditions recorded: Prostate Cancer.
Linked to the idea "Prescribe a quarter dose of abiraterone with breakfast" because the registry names Prednisone and Apalutamide and Abiraterone acetate among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Prescribe a quarter dose of abiraterone with breakfast, Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Apalutamide, Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Apalutamide, Prostate cancer and the tag pipeline.
Shares Apalutamide, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Apalutamide, Prostate cancer and the tag pipeline.